SEARCH

SEARCH BY CITATION

References

  • 1
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZC, et al., and the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:14851492. MEDLINE
  • 2
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al., and the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432. MEDLINE
  • 3
    Chemello L, Cavalletto L, Bernardinello E, Boccato S, Casarin P, Cavinato F, Urban F, et al. Comparison of thrice weekly vs daily leucocyte interferon-alpha therapy for chronic hepatitis C. J Viral Hepat 1999; 6:321327. MEDLINE
  • 4
    Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19:390399. MEDLINE
  • 5
    Xu Z-X, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFNα-2a) to healthy subjects [Abstract]. Hepatology 1998; 28(Suppl):702.
  • 6
    Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34:915923. MEDLINE
  • 7
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696699. MEDLINE
  • 8
    Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37:26252630. MEDLINE
  • 9
    Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl 1):122S127S. MEDLINE
  • 10
    Martinot-Peignoux M, Marcellin P, Poteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22:10501056. MEDLINE
  • 11
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122:161168. MEDLINE
  • 12
    Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:13071312. MEDLINE
  • 13
    Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26:780785. MEDLINE
  • 14
    Walsh KM, Good T, Cameron S, Thorburn D, McCruden EA, Mills PR, Morris AJ. Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C. Liver 1998; 18:191195. MEDLINE
  • 15
    Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997; 12:468472. MEDLINE
  • 16
    Zeuzem S, Lee JH, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27:11491156. MEDLINE
  • 17
    Roferon-A [package insert]. Nutley, NJ: Hoffmann-La Roche Inc, 1999.
  • 18
    Intron-A [package insert]. Kenilworth, NJ: Schering Corporation, 1998.
  • 19
    Talpaz M, O'Brien S, Cortes J, Giles F, Rittweger K, Hooftman L, Rakhit A, Kantarjian H. Phase I study of pegylated-interferon α-2A (PEGASYST) in patients with chronic myelogenous leukemia (CML). Blood 1999; 94(Suppl 1):530.
  • 20
    Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Safety 1994; 10:281291. MEDLINE
  • 21
    Heathcote EJ, Shiffman ML, Cooksley G, Dusheiko G, Lee SS, Balart L, Reindollar R, et al., and the Roche Peginterferon α-2a International Study Group. Multinational evaluation of the efficacy and safety of once-weekly peginterferon α-2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis [Abstract]. Hepatology 1999; 30(4Pt2):316A.